Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Chimerix Inc is a biotechnology business based in the US. Chimerix shares (CMRX) are listed on the NASDAQ and all prices are listed in US Dollars. Chimerix employs 54 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $5.51 |
|---|---|
| 52-week range | $4.75 - $11.57 |
| 50-day moving average | $6.18 |
| 200-day moving average | $7.00 |
| Wall St. target price | $18.67 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.84 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.51 from 2022-01-21
| 1 week (2022-01-14) | -8.17% |
|---|---|
| 1 month (2021-12-23) | -23.26% |
| 3 months (2021-10-22) | 3.38% |
| 6 months (2021-07-23) | -24.00% |
| 1 year (2021-01-22) | -40.63% |
|---|---|
| 2 years (2020-01-24) | 188.48% |
| 3 years (2019-01-24) | 121.29% |
| 5 years (2017-01-24) | 7.20% |
| Revenue TTM | $3.1 million |
|---|---|
| Gross profit TTM | $-30,860,000 |
| Return on assets TTM | -34.56% |
| Return on equity TTM | -154.9% |
| Profit margin | 0% |
| Book value | $1.20 |
| Market capitalisation | $521.2 million |
TTM: trailing 12 months
We're not expecting Chimerix to pay a dividend over the next 12 months.
Over the last 12 months, Chimerix's shares have ranged in value from as little as $4.75 up to $11.5696. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chimerix's is 1.3594. This would suggest that Chimerix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Chimerix, Inc. , a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.